Home » Stocks » PHVS

Pharvaris, N.V (PHVS)

Stock Price: $20.38 USD 0.32 (1.60%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 675.16M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 33.13M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $20.38
Previous Close $20.06
Change ($) 0.32
Change (%) 1.60%
Day's Open 20.88
Day's Range 19.96 - 20.78
Day's Volume 7,977
52-Week Range 19.29 - 42.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

2 days ago - GlobeNewsWire

ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...

1 week ago - GlobeNewsWire

ZUG, Switzerland, May 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists fo...

2 weeks ago - GlobeNewsWire

ZUG, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...

1 month ago - GlobeNewsWire

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...

3 months ago - GlobeNewsWire

ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the t...

3 months ago - GlobeNewsWire

Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers

3 months ago - GlobeNewsWire

ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...

4 months ago - GlobeNewsWire

ZUG, Switzerland-- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery,...

4 months ago - GlobeNewswire

Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema.

4 months ago - Pipeline Review

Pharvaris, a Dutch Phase 1 biotech developing small molecule therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

4 months ago - NASDAQ

Pharvaris, N.V has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About PHVS

Pharvaris is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. Our first molecule, PHA121, is a novel, small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema, or HAE. Bradykinin-B2-receptor inhibition is a clinically validated mechanism for the treatment of HAE. We designed PHA121 to improve upon the therapeutic profile of ex... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Berndt Modig
Employees
14
Stock Exchange
NASDAQ
Ticker Symbol
PHVS
Full Company Profile

Financial Performance

Financial numbers in millions Euro.
Financial Statements